PCM
EPZM

Penserra Capital Management’s Epizyme, Inc EPZM Stock Holding History

Penserra Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,340
Closed -$11K – 1634
2021
Q3 		$11K Buy
2,340
+20
+0.9% +$121 ﹤0.01% 1352
2021
Q2 		$19K Buy
2,320
+20
+0.9% +$169 ﹤0.01% 1166
2021
Q1 		$20K Sell
2,300
-30
-1% -$310 ﹤0.01% 973
2020
Q4 		$25K Buy
2,330
+1,464
+169% +$18.1K ﹤0.01% 823
2020
Q3 		$10K Buy
+866
New +$11.6K ﹤0.01% 817

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Penserra Capital Management's EPZM Position: Q4 2021 in Review

Penserra Capital Management sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 2,340 shares — an estimated $11K sold.

Penserra Capital Management first reported a position in EPZM in Q3 2020 and held it in 5 quarters. The position peaked at $25K in Q4 2020. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Penserra Capital Management reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,340 Epizyme, Inc shares in Q4 2021, an estimated $11K.
  • Penserra Capital Management first reported a position in Epizyme, Inc in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Epizyme, Inc position peaked at $25K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.